Effect of Interleukin-2 Receptor Antibody Induction Therapy on Survival in Renal Transplant Patients Receiving Tacrolimus
- 1 May 2020
- journal article
- research article
- Published by S. Karger AG in American Journal of Nephrology
- Vol. 51 (5), 366-372
- https://doi.org/10.1159/000506970
Abstract
Background: This study aims to assess outcomes of interleukin-2 (IL-2) receptor blocker induction therapy on allograft and patients' outcomes in standard risk recipients in the tacrolimus era, analysing data form the British Renal Transplant Registry. Methods: The study population involved all standard-risk renal transplant patients from 2000 till 2015 who were registered in the UK transplant registry and followed up till May 2018. Standard risk transplants were defined as patients with <2DR mismatch, calculated reaction frequency <20%, live donors or donors after brain death and patients with no previous renal transplantation transplant. We used inverse probability weights to adjust different covariates between the groups. Cox regression analysis for adjusted data and treatment effects model were used to assess outcomes. Results: In all, 3,597 renal transplant patients were included in the study. Two groups were identified; induction group (n = 2,858) which included patients who received IL-2 receptor blocker induction therapy and the no-induction group (n = 739). There was no significant difference between both groups in terms of estimated glomerular filtration rate (eGFR) rate at 1-year post-transplant (correlation co-efficient = 1.224, 95% CI ranges from -0.347 to 2.796). Average eGFR was 59.922 mL/min/1.73 m(2) in the induction group (SD 29.171) and 64.557 mL/min/1.73 m(2) in the no-induction groups (SD 46.763). There was no significant difference between both groups regarding graft survival at 5 years post-transplant (hazard ratio [HR] 0.944, 95% CI ranges from 0.599 to 1.485, p = 0.804), patient survival at 5 years post-transplant (HR 0.809, 95% CI ranges from 0.477 to1.372, p = 0.433). Conclusion: In the standard risk renal transplant population, the IL2 receptor blocker induction regimen does not affect eGFR at 1 year or renal and graft outcomes at 5 years.Keywords
This publication has 15 references indexed in Scilit:
- Tacrolimus, Mycophenolate Mofetil, and Low-Dose Steroids With or Without Interleukin-2 Receptor Antibody Induction Therapy: A Retrospective Cohort AnalysisTransplantation Proceedings, 2015
- Induction Therapies in Live Donor Kidney Transplantation on Tacrolimus and Mycophenolate With or Without Steroid MaintenanceClinical Journal of the American Society of Nephrology, 2015
- HLA sensitisation: can it be prevented?Pediatric Nephrology, 2014
- Basiliximab induction in patients receiving tacrolimus-based immunosuppressive regimensInternational Urology and Nephrology, 2012
- Renal Association Clinical Practice Guideline on Post-operative Care of the Kidney Transplant RecipientNephron Clinical Practice, 2011
- Long‐term vegetation responses to reintroduction and repeated use of fire in mixed‐conifer forests of the Sierra NevadaEcosphere, 2010
- Interleukin-2 receptor antibody does not reduce rejection risk in low immunological risk or tacrolimus-treated intermediate immunological risk renal transplant recipientsNephrology, 2010
- Special Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant RecipientsAmerican Journal of Transplantation, 2009
- Use of Basiliximab Induction in Low–Immunological Risk Renal Transplant Recipients Receiving Tacrolimus-Based ImmunosuppressionTransplantation Proceedings, 2009
- Early Outcomes of Thymoglobulin and Basiliximab Induction in Kidney Transplantation: Application of Statistical Approaches to Reduce Bias in Observational ComparisonsTransplantation, 2009